This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activities

Managing Patients With Moderate-to-Severe Alzheimer’s Disease: Expectations, Treatments, and Prognosis

William J. Burke, MD

Published: April 22, 2015

Article Abstract

Patients with moderate-to-severe Alzheimer’s disease and their caregivers need information on the disease stages, required monitoring, and goals of treatment. Treatments for Alzheimer’s disease include 3 cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the NMDA receptor antagonist memantine. While these treatments show benefits for cognition, global status, and activities of daily living, they are not curative. Clinicians should monitor response to treatment and adverse effects as well as emerging behavioral and psychological symptoms of dementia. Nonpharmacologic treatments for behavioral and psychological symptoms should be exhausted before trying medications, which are off-label, and risks and benefits should be discussed with patients and caregivers.

From the Stead Family Memory Center, Banner Alzheimer’s Institute, and the Department of Psychiatry, University of Arizona College of Medicine, Phoenix.

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Related Articles

Volume: 76

Quick Links: Dementia , Neurologic and Neurocognitive

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...